ALPPS的研究现状与进展  

Current status and progress of ALPPS

作　　者：周俭 彭远飞 Zhou Jian;Peng Yuanfei(Department of Liver Oncology Surgery,Zhongshan Hospital,Fudan University,Institute of Liver Cancer Research of Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院肝肿瘤外科、复旦大学肝癌研究所,上海200032

出　　处：《中华外科杂志》2025年第4期265-270,共6页Chinese Journal of Surgery

摘　　要：手术切除是肝癌患者长期生存的主要治疗方式,但许多患者因为预计余肝体积不足而无法手术切除肿瘤。诱导余肝增生后再切除肿瘤的二步肝切除是预计余肝体积不足患者的主要治疗策略之一。联合肝脏分隔和门静脉结扎的二步肝切除术(ALPPS)是诱导余肝增生的一种重要创新术式,具有诱导肝脏快速增生、肿瘤切除率高等优点。但早年ALPPS也曾因手术并发症发生率和病死率高等问题引发争议。历经十余年的发展,ALPPS进展迅速,安全性已显著改善,肿瘤学获益等问题亦已基本明晰。本文对ALPPS的现状与进展进行阐述。Surgical resection is the mainstay of curative treatment for long-term survival of patients with liver cancer.However,many patients are excluded for surgical resection due to insufficient future liver remnant(FLR).The two-stage hepatectomy(induction of FLR hypertrophy followed by tumor resection)is one of the main treatment strategies for insufficient FLR.The new associating liver partition and portal vein ligation for staged hepatectomy(ALPPS)is an important innovative procedure for inducing FLR hypertrophy,which has the advantages of rapid and significant induction of FLR hypertrophy as well as high tumor resection rate,but it was controversial in the early years due to high postoperative morbidity and mortality.After more than 10 years of development,ALPPS has made tremendous advance.Surgical safety of ALPPS has been significantly improved,and oncological benefits and other issues have been largely clarified.This article aims to introduce the current status and progress of ALPPS.

关 键 词：肝肿瘤 外科手术 预计余肝体积 联合肝脏分隔和门静脉结扎的二步肝切除术 

分 类 号：R735.7[医药卫生—肿瘤]